[First clinical and oncological experiences with triplet therapy for high-volume metastatic hormone-sensitive prostate cancer].

Autor: Wenzel M; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland. Mike.Wenzel@kgu.de., Hoeh B; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland., Kasparek J; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland., Humke C; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland., von Koskull S; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland., Chun FKH; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland., Banek S; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland., Mandel P; Klinik für Urologie, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Deutschland. Philipp.Mandel@kgu.de.
Jazyk: němčina
Zdroj: Urologie (Heidelberg, Germany) [Urologie] 2024 Mar; Vol. 63 (3), pp. 254-261. Date of Electronic Publication: 2023 Dec 21.
DOI: 10.1007/s00120-023-02253-8
Abstrakt: Background: Treatment with androgen deprivation therapy (ADT) plus extended hormone therapy (ARTA) is the standard of care for metastatic hormone-sensitive prostate cancer (mHSPC). Recent data of triplet combination therapies of ADT + ARTA (abiraterone/darolutamide) + docetaxel chemotherapy showed a survival advantage for specific mHSPC patient subgroups.
Purpose: What treatment response is observed in real-world mHSPC setting using triplet combination therapy and what are the expected side effects?
Results: All patients receiving triplet combination therapy of ADT + ARTA (abiraterone/darolutamide) + docetaxel were included in the current study. A total of 14 patients with a median age of 62 years and 10/14 abiraterone or 4/14 darolutamide therapy could be included. The median PSA before initiation of therapy was 77 ng/ml (IQR 44-150). Overall, 86% of patients had a PSA response > 90% and the median PSA nadir was 0.3 ng/ml. Severe adverse events (grade III) during triplet therapy occurred in two patients (35,7%) with respectively febrile neutropenia 7.1% (1/14) and diarrhea with infection 7.1%. Other low grade adverse events (grade I/II) consisted of polyneuropathy (1/14), mucositis (1/14), xerostomia (1/14), weight loss (1/14) and fatigue (3/14) were detected. Chemotherapy was interrupted in one patient due to adverse events. After a median follow-up of ten months (IQR: 7-17), two patients (14.2%) showed progression to castration resistance.
Conclusion: Triplet therapy shows a very good PSA response in clinical practice. Adverse events during therapy are mainly triggered by classical chemotherapy-known side effects.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: